Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer.

ABSTRACT: Interventions: HLA B40(+) HLA B51(+) PSK(-) PSK(+): PSK was administered orally from 14 days after gastrectomy at a dose of 3.0g/day and at least at a dose of over 270g. Per os fluoropyrimidine prodru (5-FU 150mg/day or UFT (300mg/day) was administered orally from 14 days after gastrectomy over 1 year. MMC was injected intravenously 0.4 mg/Kg intraoperatively and/or 0.2 mg/Kg on postoperative day 1. Primary outcome(s): Five year overall survival after gastrectomy Study Design: Parallel Randomized

DISEASE(S): Gastric Cancer Colorectal Cancer

PROVIDER: 2723206 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Randomized controlled trial to evaluate the prediction of the immunotherapy response based on HLA-type.

Project description:Interventions: R0: Gastrectomy alone Chemotherapy: F/MF PSK group: F/MF and PSK R(+) Chemotherapy: MF/CF PSK group: MF/CF and PSK PSK was administered orally from 14 days after gastrectomy at a dose of 3.0g/day and at least at a dose of over 270g. Fluoropyrimidine prodrug (5-FU 150mg/day or UFT (300mg/day or TS1 40-80mg/day) was administered orally from 14 days after gastrectomy over 1 year. MMC was injected intravenously 0.4 mg/Kg and/or 0.2 mg/Kg intraoperatively within 1 month after gastrectomy. CDDP (40-60mg/m2/W 4 times) was administered intravenously after gastrectomy starting from July 1996. PSK(-) PSK(+) Primary outcome(s): Evaluation of overall survival and QOL in patients given therapies with or without PSK based on HLA category types. Study Design: Parallel Randomized

| 2723211 | ecrin-mdr-crc

Cardiac Effects of Rosiglitazone in Male Wistar Rats

Project description:Rosiglitazone, a peroxisome proliferator-activated receptor g (PPARg) agonist of the thiazolidinedione class, is a major insulin-sensitizing drug widely used to treat type-2 diabetes. Rosiglitazone causes myocardial hypertrophy in rodents and increases the risk of cardiac events in man. To better characterize its cardiac effects, male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone. Male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone once per day for 14 days. Samples were obtained 6, 24, 168 or 336 hours after the final treatment.

2010-07-29 | E-GEOD-22553 | biostudies-arrayexpress

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed R6/2 mice.

Project description:R6/2 and WT mice treated orally twice a day with vehicle (10% HPβCD), and R6/2 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 - 12 weeks of age.

2017-09-23 | GSE104086 | GEO

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed Q175 mice.

Project description:WT and Q175 heterozygous (het) mice treated orally twice a day with vehicle (10% HPβCD), and Q175 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 weeks to 6 months of age.

2017-09-23 | GSE104064 | GEO

Ethoxysanguinarine, Baicalin, Gastrodin and Valsartan treatment lower Angiotensin-II-induced blood pressure

Project description:The goals of this study is to identify the differential expressed genes in abdominal aorta of C57BL/6 mice with or without Angiotensin II (AngII) treatment, and compare the differential expressed genes in the abdominal aorta of Ang II infused C57BL/6 mice after Ethoxysanguinarine (ETH), Baicalin (BAI), Gastrodin (GAS) or valsartan (VAL) treatment. Briefly, the mice (n=30) were randomly divided into 6 groups: control, AngII, AngII + ETH, AngII + BAI, AngII + GAS and AngII + VAL groups (n=5 for each group). Mice in Control and AngII groups were infused with saline and 500 ng/kg/min of AngII respectively, and orally administrated with saline; the mice in AngII + ETH, AngII + BAI and AngII + GAS groups were infused with AngII (500 ng/kg/min) and orally administrated with 5 mg/kg /day of ETH, BAI or GAS daily for total 4 weeks. The mice in AngII + VAL group were infused with AngII (500 ng/kg/min) and orally administrated with 10.4mg/kg /day of VAL. Then the abdominal aortas were used to identify differentially expressed genes among different groups.

2021-05-14 | GSE174386 | GEO

RNA sequencing to detect the differentially expressed genes in AngII infused mice after Ethoxysanguinarine, Baicalin, Gastrodin or Valsartan treatment

Project description:The goals of this study is to identify the differential expressed genes in cardiac tissue of C57BL/6 mice with or without Angiotensin II (AngII) treatment, and compare the differential expressed genes in the cardiac tissue of Ang II infused C57BL/6 mice after Ethoxysanguinarine (ETH), Baicalin (BAI), Gastrodin (GAS) or valsartan (VAL) treatment. Briefly, the mice (n=30) were randomly divided into 6 groups: control, AngII, AngII + ETH, AngII + BAI, AngII + GAS and AngII + VAL groups (n=5 for each group). Mice in Control and AngII groups were infused with saline and 500 ng/kg/min of AngII respectively, and orally administrated with saline; the mice in AngII + ETH, AngII + BAI and AngII + GAS groups were infused with AngII (500 ng/kg/min) and orally administrated with 5 mg/kg /day of ETH, BAI or GAS daily for total 4 weeks. The mice in AngII + VAL group were infused with AngII (500 ng/kg/min) and orally administrated with 10.4mg/kg /day of VAL. Then the cardiac tissues were used to identify differentially expressed genes among different groups.

2023-01-09 | GSE193504 | GEO

RNA sequencing to detect the differentially expressed genes in AngII infused mice model after QDG treatment.

Project description:The mice (n=15) were randomly divided into 3 groups: Control, Ang Ⅱ, and Ang Ⅱ+QDG groups (n = 5 for each group). Mice in Control and Ang Ⅱ groups were infused with saline or 500 ng/kg/min of Ang Ⅱ respectively, and orally administrated with saline; while mice in Ang Ⅱ + QDG group were infused with Ang Ⅱ (500 ng/kg/min) and orally administrated with 1.145 g/kg /day of QDG for 2 weeks. Then the cardiac tissues were used to identify differentially expressed genes among different groups.

2021-08-31 | GSE157127 | GEO

Genome-wide methylation changes in maternal microchimeric cells from Mmc+ and Mmclow offspring mice

Project description:During mammalian pregnancy, immune cells are vertically transferred from mother to fetus. The functional role of these maternal microchimeric cells (MMc) is largely unknown. We show that MMc induce a preferential differentiation of hematopoietic stem and progenitor cells towards myelopoiesis in bone marrow of fetal mice, and improves resilience against cytomegalovirus infection in neonates. In humans, low MMc counts in cord blood are associated with an increased number of infections in the first year of life primarily in male newborns. Taken together, MMc boost neonatal immunity in mice and humans to mitigate the risk for early life infections.

2020-06-04 | GSE151725 | GEO

Gene expression profiling using RNA-Seq data of MMTV-Wnt1 tumor tissue from mice treated with E7386

Project description:We conducted an RNA-Seq analysis using total RNA extracted from MMTV-Wnt1 tumor tissues resected from mice orally administered E7386 at 25 or 50 mg/kg twice daily, or vehicle, for 3 days (Day 4) or 7 days (Day 8) and examined the differentially expressed gene levels compared with vehicle at days 4 and 8.

2020-12-21 | GSE158713 | GEO

Trancsriptional profiling of B16-C10 tumors treated with PBS, oBHV or MMC+oBHV.

Project description:To explore the mechanism of action upon addition of MMC to oBHV therapy, unbiased transcriptional profiling was conducted on B16-C10 tumors treated with PBS, oBHV or MMC+oBHV harvested at day 5.

2023-02-17 | GSE223637 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data